• 研究室概要
• 主要研究テーマ
• スタッフ
• 主な研究実績
• 主な研究費取得状況

当分野では、がん組織中の稀少細胞に着目したがん治療方法の開発に関する研究、臨床薬物動態学に基づいた抗菌薬および抗ウイルス薬の投与量設計に関する研究、神経回路網形成および高次脳機能発現の分子機構に関する研究など基礎から臨床まで幅広く研究を行っています。

研究室概要

分野サイト

連絡先

主要研究テーマ

スタッフ

教授

研究者総覧 リポジトリ

准教授

研究者総覧 リポジトリ

主な研究実績

寺薗　英之

1. Higashi K, Sonoda Y, Kaku N, Fujii F, Yamashita F, Lee S, Tocan V, Ebihara G, Matsuoka W, Tetsuhara K, Sonoda M, Chong PF, Mushimoto Y, Kojima-Ishii K, Ishimura M, Koga Y, Fukuta A, Tsuchihashi NA, Kikuchi Y, Karashima T, Sawada T, Hotta T, Yoshimitsu M, Terazono H, Tajiri T, Nakagawa T, Sakai Y, Nakamura K, Ohga S.: Rapid and long-lasting efficacy of high-dose ambroxol therapy for neuronopathic Gaucher disease: A case report and literature review. Mol Genet Genomic Med., 12(4):e2427. (2024)
2. Nagahama J, Nishikawa T, Nakamura T, Nakagawa S, Kodama Y, Terazono H, Wakamatsu M, Muramatsu H, Yamashiro Y, Kanno H, Okamoto Y. Severe β-thalassemia (Hb Zunyi) mimicking congenital dyserythropoietic anemia. 70(12):e30706. (2023)
3. Tabata K, Aoki M, Miyata R, Umehara T, Harada-Takeda A, Kamimura G, Nagata T, Okizono R, Terazono H, Takeda Y, Suetsugu T, Ueda K, Sato M.: Successful Treatment with Osimertinib Based on Therapeutic Drug Monitoring in a Hemodialysis Patient with Non-Small Cell Lung Cancer: A Case Report., 22;16(1):705-710 (2023)
4. Kanazawa N, Shigemi A, Amadatsu N, Arimura K, Shimono S, Oda K, Chuang VTG, Matsumoto K, Kawamura H, Terazono H.: A cohort study of the risk factors and the target AUC to avoid vancomycin-associated acute kidney injury in pediatric patients., 30(4):323-328 (2023)
5. Terazono H, Tsuchiya M, Maki Y, Yoshikawa N, Kawahara Y, Nishimura K, Shinohara K, Ogawa D, Mori R, Iwamoto Y, Itagaki F, Masuko H, Yonemura M, Uchida M: Evaluation of a Webinar for Pharmacists Learning Basic Clinical-Oncology during COVID-19 Pandemic in Japan. Biol. Pharm. Bull., 45(7):856-862. (2022)
6. Umezaki Y, Matsumoto K, Ikawa K, Yokoyama Y, Enoki Y, Shigemi A, Watanabe E, Nakamura K, Ueno K, Terazono H, Morikawa N, Takeda Y: Concentration-Dependent Activity of Pazufloxacin against Pseudomonas aeruginosa: An In Vivo Pharmacokinetic/Pharmacodynamic Study. Antibiotics, 21;11(7):982. (2022)
7. Matsubara K, Matsumoto K, Yokoyama Y, Watanabe E, Enoki Y, Shigemi A, Ikawa K, Terazono H, Morikawa N, Ohshige T, Takeda Y: Dosing Optimization of Ampicillin-Sulbactam Based on Cystatin C in Elderly Patients with Pneumonia. Biol. Pharm. Bull., 44(5):732-736. (2021)
8. Tsuchiya M, Terazono H, Maki Y, Yoshikawa N, Kawahara Y, Nishimura K, Shinohara K, Ogawa D, Mori R, Iwamoto Y, Itagaki F, Masuko H, Yonemura M, Uchida M: Evaluation of a web-based educational programme for pharmacists during the COVID-19 pandemic in Japan. J. Clin. Pharm. Ther., 46(6):1743-1749. (2021)
9. Takahashi T, Terazono H, Suetsugu T, Sugawara H, Arima J, Nitta M, Tanabe T, Okutsu K, Ikeda R, Mizuno K, Inoue H, Takeda Y: High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction. Cancers, 8;13(14):3425. (2021)
10. Watanabe E, Matsumoto K, Ikawa K, Yokoyama Y, Shigemi A, Enoki Y, Umezaki Y, Nakamura K, Ueno K, Terazono H, Morikawa N, Takeda Y: Pharmacokinetic/pharmacodynamic evaluation of teicoplanin against Staphylococcus aureus in a murine thigh infection model. J. Glob. Antimicrob. Resist., 24:83-87, (2021)
11. Nishizawa Y, Ikeda R, Yamamoto M, Kawahara K, Shinsato Y, Minami K, Nitta M, Terazono H, Akiyama SI, Furukawa T, Takeda Y: 5-Aza-2-deoxycytidine Enhances the Sensitivity of 5-Fluorouracil by Demethylation of the Thymidine Phosphorylase Promoter. Anticancer Res., 39(8):4129-4136, (2019)
12. Girault M., Kim H., Arakawa H., Matsuura K., Odaka M., Hattori A., Terazono H., Yasuda K.: An on-chip imaging droplet-sorting system: a real-time shape recognition method to screen target cells in droplets with single cell resolution. Sci. Rep., 6: 7:40072, (2017)
13. Girault M., Hattori A., Kim H., Matsuura K., Odaka M., Terazono H., Yasuda K.: Algorithm for the precise detection of single and cluster cells in microfluidic applications. Cytometry A, 89(8): 731-41, (2016)
14. Terazono H., Kim H., Nomura F., Yasuda K.: Development of a microprocessing-assisted cell-systematic evolution of ligands by exponential enrichment method for human umbilical vein endothelial cells. Jpn. J. Appl. Phys., 55: 06GN03, (2016)

末次　王卓

1. Matsukane R, Nakamura S, Minami H, Tsubouchi K, Yoneshima Y, Hata K, Yasukochi S, Suetsugu K, Okamoto I, Hirota T.: Krebs von den Lungen-6 surveillance in immune checkpoint inhibitor-induced pneumonitis. J Immunother Cancer., Dec 22; 12(12) :e010114, (2024)
2. Yamada T, Belabbas T, Suetsugu K, Hirota T, Mori Y, Kato K, Akashi K, Egashira N, Ieiri I : Influencing factors on serum posaconazole concentrations in hematologic malignancies receiving delayed-release tablets. Ther Drug Monit., Oct 1;46(5):603-610, (2024)
3. Fujita Y, Murai M, Muraki S, Suetsugu K, Tsuchiya Y, Hirota T, Matsunaga N, Ieiri I: Population Pharmacokinetic Analysis of Drug-Drug Interactions Between Perampanel and Carbamazepine Using Enzyme Induction Model in Epileptic Patients. Therapeutic Drug Monitoring, 45(5):653-659, (2023)
4. Matsukane R, Suetsugu K, Hata K, Matsuda K, Nakao S, Minami H, Watanabe H, Hirota T, Egashira N, Ieiri I:Systematic surveillance of immune-related adverse events in clinical practice and impact of subsequent steroid medication on survival outcomes.International Journal of Clinical Oncology 28(7):860-871, (2023)
5. Belabbas T, Yamada T, Egashira N, Hirota T, Suetsugu K, Mori Y, Kato K, Akashi K, Ieiri I:Population pharmacokinetic model and dosing optimization of vancomycin in hematologic malignancies with neutropenia and augmented renal clearance.Journal of Infection and Chemotherapy 29(4):391-400, (2023)
6. Suetsugu K, Muraki S, Fukumoto J, Matsukane R, Mori Y, Hirota T, Miyamoto T, Egashira N, Akashi K, Ieiri I: Effects of Letermovir and/or Methylprednisolone Coadministration on Voriconazole Pharmacokinetics in Hematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study. Drugs in R&D 21(4):419-429, (2021)
7. Nagata K, Tsuji T, Suetsugu K, Muraoka K, Watanabe H, Kanaya A, Egashira N, Ieiri I:Detection of overdose and underdose prescriptions-An unsupervised machine learning approach.PLoS One 16(11):e0260315, (2021)
8. Matsukane R, Watanabe H, Hata K, Suetsugu K, Tsuji T, Egashira N,Nakanishi Y, Okamoto I, Ieiri I:Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy.Scientific Reports 11(1):15057, (2021)
9. Matsukane R, Watanabe H, Minami H, Hata K, Suetsugu K, Tsuji T, Masuda S, Okamoto I, Nakagawa T, Ito T, Eto M, Mori M, Nakanishi Y, Egashira N:Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events.Scientific Reports 11(1):1324, (2021)
10. Hata K, Suetsugu K, Egashira N, Makihara Y, Itoh S, Yoshizumi T, Tanaka M, Kohjima M, Watanabe H, Masuda S, Ieiri I:Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma.Cancer Chemotherapy and Pharmacology 86(6):803-813, (2020)

主な研究費取得状況

寺薗　英之

末次　王卓

分野サイト